Pharmaceutical rebate debated in Germany

05/1/2013 | Financial Times (tiered subscription model)

The expiration of Germany's 16% rebate for pharmaceuticals at the end of 2013 is prompting debate about its necessity. The country's Statutory Health Insurance funds, which benefit from the rebate, made a huge surplus last year, according to price consultant Andreas Guhl. Contracts will expire Dec. 31, so a decision will likely be made about August to October. "I can't see the likelihood of the rebate disappearing completely," Guhl said.

View Full Article in:

Financial Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
Washington DC, DC